182 related articles for article (PubMed ID: 37778414)
1. Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.
Zhang S; Zhao Y; Wang X; Qi C; Tian J; Zou Z
Life Sci; 2023 Nov; 332():122131. PubMed ID: 37778414
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
3. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity.
Patel A; Seraia E; Ebner D; Ryan AJ
Int J Cancer; 2020 Sep; 147(5):1474-1484. PubMed ID: 32159854
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
7. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Mei L; Zhang J; He K; Zhang J
J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
[TBL] [Abstract][Full Text] [Related]
8. Dormant origin signaling during unperturbed replication.
Moiseeva TN; Bakkenist CJ
DNA Repair (Amst); 2019 Sep; 81():102655. PubMed ID: 31311769
[TBL] [Abstract][Full Text] [Related]
9. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.
Ngoi NYL; Peng G; Yap TA
Annu Rev Med; 2022 Jan; 73():231-250. PubMed ID: 34644155
[TBL] [Abstract][Full Text] [Related]
10. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
Guo Y; Wang J; Benedict B; Yang C; van Gemert F; Ma X; Gao D; Wang H; Zhang S; Lieftink C; Beijersbergen RL; Te Riele H; Qiao X; Gao Q; Sun C; Qin W; Bernards R; Wang C
Genome Med; 2021 Oct; 13(1):166. PubMed ID: 34663432
[TBL] [Abstract][Full Text] [Related]
11. ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1.
Moiseeva T; Hood B; Schamus S; O'Connor MJ; Conrads TP; Bakkenist CJ
Nat Commun; 2017 Nov; 8(1):1392. PubMed ID: 29123096
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
[TBL] [Abstract][Full Text] [Related]
13. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
14. A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress.
Egger T; Bordignon B; Coquelle A
Sci Rep; 2022 Mar; 12(1):5422. PubMed ID: 35361811
[TBL] [Abstract][Full Text] [Related]
15. Targeting ATR in DNA damage response and cancer therapeutics.
Fokas E; Prevo R; Hammond EM; Brunner TB; McKenna WG; Muschel RJ
Cancer Treat Rev; 2014 Feb; 40(1):109-17. PubMed ID: 23583268
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
17. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
18. ATR prohibits replication catastrophe by preventing global exhaustion of RPA.
Toledo LI; Altmeyer M; Rask MB; Lukas C; Larsen DH; Povlsen LK; Bekker-Jensen S; Mailand N; Bartek J; Lukas J
Cell; 2013 Nov; 155(5):1088-103. PubMed ID: 24267891
[TBL] [Abstract][Full Text] [Related]
19. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
Moolmuang B; Ruchirawat M
J Pharm Pharmacol; 2021 Mar; 73(1):40-51. PubMed ID: 33791808
[TBL] [Abstract][Full Text] [Related]
20. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]